Graniz Inj
Granisetron Inj
Strength: 3MG
Pack Size: 1 vial
Drug Class: Antiemetics, Selective 5-HT3 Antagonist
Dosage and Administration:
Cytostatic Therapy
The recommended dosage for Granisetron injection is 40ug/kg administration intravenously within 30 minutes before initiation of chemotherapy. Injection may be administered intraveno- usly either undiluted over 30 seconds or diluted with 5 minutes.
One additional dose of 40ug/kg body weight (up to 3mg) may be administered within a 24-hour period if required. This additional dose should be administered over five minutes. The administration should be completed prior to the start of cytostatic therapy.
Renally impaired. No special requirements apply. Hepatically impaired: N special requirements apply.
Post Operative Nausea and vomiting
Adults: For prevention in adults, a single dose of 1mg of Granisetron injection should be diluted to 5ml and administered as a slow intravenous injection (over 30 seconds) Administrations should be completed prior to induction of anesthesia.
For the treatment of established postoperative nausea and vomiting in adults, a single dose of 1mg of Granisetron injection should be diluted to 5ml and administered by slow intravenous injection (over 30 seconds).
Children: There is no experience in the use of Granisetron injection in the prevention and treatment of postoperative nausea and vomiting in children under 12 years of age. Granise- tron injection is not therefore recommended for the treatment of postoperative nausea and vomiting in this age group.
Elderly: As for adults.
Renally impaired: As for adults.
Hepatically impaired : As for adults.
Instructions for use & handling :
As a general precaution, GRANIZ injection should not be mixed in solution with other drugs. Prophylactic administration of Granisetron injection should be completed prior to the start of cytostatic therapy or induction of anesthesia.
Preparation of the infusion :
Children: To prepare the dose of 40ug/kg the appropriate volume is withdrawn and diluted with infusion fluid to a total volume of 10 to 30 ml. Any one of the following solutions may be used: 0.9% w/v Sodium Chloride Injection 0.18% w/v Sodium Chloride Injection and 4% w/v Glucose: Injection; 5% w/v Glucose Injection; Hartman’s Solution for injection’ Adults: To prepare a dose of 1mg, 1ml should be withdrawn from the vial and diluted to 5ml with 0.9% w/v Sodium Chloride Injection. No other diluents should be used. Ideally, Intravenous infusion of Granisetron injection should be prepared at the time of administration.
After dilution (see above). or when the container is opened for the first time, the shelf life is 24 hours when stored at ambient temperature in normal indoor illumination, protected from direct sunlight. It must not be used after 24 hours. If to be stored after preparation. Granisetron infusions must be prepared under aseptic conditions.
Cold Storage: no
Graniz Injection is a prescription medicine used to treat the symptoms of Nausea and Vomiting caused by Chemotherapy, Radiation or Postoperative. Graniz Injection may be used alone or with other medications.
Graniz Injection belongs to a class of drugs called Antiemetics, Selective 5-HT3 Antagonist.
Chemically Granisetron Hydrochloride is 1-Methyl-N-[(3-endo)-9-methyl-9-aza bicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide hydrochloride.
Structural formula:
Granisetron injection is indicated for the prevention or treatment of nausea and vomiting with the treatment of cancer by radiotherapy and chemotherapy and for the prevention of nausea and vomiting.
Usage:
As directed by the physician.
Granisetron is a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1; 5-HT1A; 5-HT1B/C; 5-HT2; for alpha1-, alpha2– or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors.Animal pharmacological studies have shown that in binding to 5-HT3 receptors, granisetron blocks serotonin stimulation, and is effective in alleviating the retching and vomiting evoked by cytostatic treatment.
- Read the label carefully before use
- Store below 30°C. Protect from light. Do not freeze.
- Keep out of the reach of children
Pregnancy & Lactation
Whilst animal studies have shown no teratogenic effects. there is no experience of Granisetron injection in human pregnancy. Therefore Granisetron injection should not be administered to pregnant women unless there are compelling reasons. There is no data on the excretion of Granisetron in breast milk. Breastfeeding should, therefore, be discontinued during therapy.
